GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Cyclically Adjusted PB Ratio

Daiichinkyo Co (Daiichinkyo Co) Cyclically Adjusted PB Ratio : 6.64 (As of Apr. 28, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Daiichinkyo Co's current share price is $31.85. Daiichinkyo Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $4.80. Daiichinkyo Co's Cyclically Adjusted PB Ratio for today is 6.64.

The historical rank and industry rank for Daiichinkyo Co's Cyclically Adjusted PB Ratio or its related term are showing as below:

DSKYF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.57   Med: 4.51   Max: 7.61
Current: 7.11

During the past years, Daiichinkyo Co's highest Cyclically Adjusted PB Ratio was 7.61. The lowest was 1.57. And the median was 4.51.

DSKYF's Cyclically Adjusted PB Ratio is ranked worse than
90.11% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs DSKYF: 7.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Daiichinkyo Co's adjusted book value per share data for the three months ended in Mar. 2024 was $5.876. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.80 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Daiichinkyo Co Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Daiichinkyo Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Cyclically Adjusted PB Ratio Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.59 5.74 4.46 7.39 6.76

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.39 6.83 6.03 5.59 6.76

Competitive Comparison of Daiichinkyo Co's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Cyclically Adjusted PB Ratio falls into.



Daiichinkyo Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Daiichinkyo Co's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=31.85/4.8
=6.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiichinkyo Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Daiichinkyo Co's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.876/107.2000*107.2000
=5.876

Current CPI (Mar. 2024) = 107.2000.

Daiichinkyo Co Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.527 98.000 4.952
201409 4.552 98.500 4.954
201412 4.393 97.900 4.810
201503 5.128 97.900 5.615
201506 4.890 98.400 5.327
201509 4.995 98.500 5.436
201512 5.035 98.100 5.502
201603 5.319 97.900 5.824
201606 5.490 98.100 5.999
201609 5.563 98.000 6.085
201612 5.154 98.400 5.615
201703 5.234 98.100 5.720
201706 5.396 98.500 5.873
201709 5.439 98.800 5.901
201712 5.405 99.400 5.829
201803 5.499 99.200 5.942
201806 5.665 99.200 6.122
201809 5.730 99.900 6.149
201812 5.665 99.700 6.091
201903 5.785 99.700 6.220
201906 5.971 99.800 6.414
201909 6.088 100.100 6.520
201912 6.271 100.500 6.689
202003 6.238 100.300 6.667
202006 6.290 99.900 6.750
202009 6.495 99.900 6.970
202012 6.433 99.300 6.945
202103 6.107 99.900 6.553
202106 6.696 99.500 7.214
202109 6.861 100.100 7.348
202112 6.736 100.100 7.214
202203 5.943 101.100 6.302
202206 5.453 101.800 5.742
202209 5.342 103.100 5.554
202212 5.469 104.100 5.632
202303 5.642 104.400 5.793
202306 5.645 105.200 5.752
202309 5.623 106.200 5.676
202312 5.746 106.800 5.768
202403 5.876 107.200 5.876

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Daiichinkyo Co  (OTCPK:DSKYF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Daiichinkyo Co Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.